Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis [Poster]

MLA

Riedl, J. M., et al. Gemcitabine/Nab-Paclitaxel versus (Modified) FOLFIRINOX for Palliative First-Line Treatment of Advanced Pancreatic Cancer: A Propensity Score Analysis [Poster]. Jan. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3341..e0739b2df1566291095be23be060d205&authtype=sso&custid=ns315887.

APA

Riedl, J. M., Posch, F., Horvath, L., Gantschnigg, A., Renneberg, F., Schwarzenbacher, E., Moik, F., Barth, D., Stotz, M., Schaberl-Moser, R., Pichler, M., Stöger, H., Greil, R., Djanani, A., Schlick, K., & Gerger, A. (2020). Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis [Poster].

Chicago

Riedl, J.M., F. Posch, L. Horvath, A. Gantschnigg, F. Renneberg, E. Schwarzenbacher, F. Moik, et al. 2020. “Gemcitabine/Nab-Paclitaxel versus (Modified) FOLFIRINOX for Palliative First-Line Treatment of Advanced Pancreatic Cancer: A Propensity Score Analysis [Poster],” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......3341..e0739b2df1566291095be23be060d205&authtype=sso&custid=ns315887.